Proteins are the primary functional units of biology and the direct targets of most drugs, yet 49 there is limited knowledge of the genetic factors determining inter-individual variation in 50 protein levels. Here we reveal the genetic architecture of the human plasma proteome, testing 51 10.6 million DNA variants against levels of 2,994 proteins in 3,301 individuals. We identify 52 1,927 genetic associations with 1,478 proteins, a 4-fold increase on existing knowledge, 53
Introduction
Of the proteins for which we identified a pQTL, 88% had either cis (n=374) or trans (n=925) 111 associations only, while 12% (n=179) had both. The majority of significantly associated 112 proteins (75%; n=1,113) had a single pQTL, while 20% had two and 5% had more than two 113 ( Figure 1c ). To detect multiple signals at the same locus we used stepwise conditional 114 analysis, identifying 2,658 conditionally significant associations ( Supplementary Table 2 ). Of 115 the 1,927 locus-protein associations, 414 (21%) had multiple conditionally significant signals 116 ( Figure 1d ), of which 255 were cis. 117 118 Genetic variants that change the protein structure may result in apparent pQTLs due to 119 altered aptamer binding rather than true quantitative differences in protein levels. Using 120 bioinformatic approaches to evaluate the extent to which cis pQTLs might reflect technical 121 effects (Methods) we found that 91% of pQTLs were unlikely to be influenced by differential 122 aptamer binding ( Supplementary Tables 1 and 3 ). Furthermore, in sub-studies that involved 123 immunoassays, we found strongly concordant genotype-protein associations (Supplementary 124 Note). Even where apparent pQTLs do arise from alternative protein structure that may affect 125 aptamer binding rather than differences in protein abundance, such signals may be 126 functionally significant. 127 frequency (MAF 1-5%) variants. Of the 31 strongest pQTLs (per-allele effect size >1.5 136 standard deviations), 25 were rare or low-frequency variants. 137 138 pQTLs were strongly enriched for missense variants (p<0.0001) and for location in 3' 139 untranslated (p=0.0025) or splice regions (p=0.0004) (Figure 1g , Extended Data Figure 2) . 140
To assess whether pQTLs were enriched within regulatory elements from a wide range of cell 141 types and tissues 15-17 , we used GARFIELD 18 (Methods). We found strong ( ≥ 3-fold, 142 p<5x10 -5 ) enrichment of pQTLs in blood cells -unsurprisingly given our use of plasma -at 143 features indicative of transcriptional activation (Extended Data Figure 3 , Supplementary 144 Table 4 ). We also found enrichment at hepatocyte regulatory elements, consistent with the 145 liver's role in producing many secreted proteins. 146 147 Overlap of loci for gene expression and protein levels 148 A fundamental biological question is the extent to which genetic associations with plasma 149 protein levels are driven by effects at the transcription level, rather than other mechanisms, 150 such as altered protein clearance or cleavage of membrane receptor proteins from the cell 151 surface. We therefore cross-referenced our cis pQTLs with a wide range of publicly available 152 eQTL studies involving >30 tissues or cell types ( Supplementary Table 5 ) using 153 PhenoScanner 8 . 40% (n=224) of cis pQTLs had an association with expression of the same 154 gene in at least one tissue ( Supplementary Table 6 ), consistent with similar comparisons 155 within lymphoblastoid cell lines (LCLs) 19 . The greatest overlaps were found in whole blood 156 (n=117), liver (n=70) and LCLs (n=52), consistent with biological expectation, but also likely 157 driven by the larger sample sizes for expression studies of these cell types. Cis pQTLs were 158 significantly enriched (p<0.0001) for eQTLs for the corresponding gene (mean 20% versus 159 2% in a background permuted set; Methods, Supplementary Table 7 ). To address the 160 converse (i.e., to what extent do eQTLs translate into pQTLs), we used a subset of well-161 powered eQTL studies in relevant tissues (whole blood, LCLs, liver and monocytes [20] [21] [22] [23] ). Of 162 the strongest cis eQTLs (p<1.5x10 -11 ), 12.2% of those in whole blood were also cis pQTLs, 163 21.3% for LCLs, 14.8% for liver and 14.7% for monocytes. 164 165 Comparisons between eQTL and pQTL studies have inherent limitations due to differences in 166 the tissues, sample sizes and technological platforms used. Moreover, plasma protein levels 167 may not reflect levels within tissues or cells. Nevertheless, our data suggest that plasma 168 protein abundance is often, but not exclusively, driven by regulation of mRNA. Our finding 169 that pQTLs are enriched in gene regulatory regions supports the notion that transcription has 170 a major role. Cis pQTLs without corresponding cis eQTLs may be underpinned by effects not 171 captured at the mRNA level, such as differences in protein stability, degradation, binding, 172 secretion, or clearance from circulation. 173 174 Using trans pQTLs to illuminate biological pathways 175 Trans pQTLs are particularly useful for understanding biological relationships between 176 proteins if a causal gene at the trans-associated genetic locus can be identified. To this end, 177
we used a combination of databases of molecular pathways and protein-protein interaction 178 networks, and functional genomic data that include variant annotation, eQTL and 179 chromosome conformation capture, to link trans-associated variants to potential causal genes 180 (Methods, Supplementary Table 8 , Extended Data Figure 4 ). Of the 764 protein-associated 181 regions, 262 had trans associations with 1,104 proteins. We replicated previously reported 182 trans associations including TMPRSS6 with transferrin receptor protein 1 24 and SORT1 with 183 granulins 25 . Most (82%) trans loci were associated with fewer than four proteins. However, 184
we observed twelve regions with more than 20 associated proteins (Figure 1a , Extended Data 185 Figure 5 ), including well-known pleiotropic loci (e.g., ABO, CFH, APOE, KLKB1) and loci 186 associated with many correlated proteins (e.g., the locus containing the transcription factor 187 gene, ZFPM2). 188
189
We identified a number of novel associations with strong biological plausibility 190 (Supplementary Table 9 , Supplementary Note). Growth differentiation factor 8 (GDF8, more 191 commonly known as myostatin) provides one such example. Because insufficient myostatin 192 has been shown to result in excessive muscle growth 26 , myostatin inhibition has emerged as a 193 promising therapeutic strategy for treatment of conditions characterised by muscle weakness, 194 such as muscular dystrophy 27 . We identified a common allele (rs11079936:C) near 195 WFIKKN2 that is associated in trans with lower levels of plasma GDF11/8 (p=7.9x10 -12 ), as 196 well as in cis with lower levels of plasma WFIKKN2 (p=6.9x10 -136 , Supplementary Table 1 , 197 Figure 2). The trans association attenuated completely upon adjustment for levels of 198 WFIKKN2 (p=0.7), while the cis association remained significant after adjustment for 199 GDF11/8 (p=7.2x10 -113 ), suggesting that WFIKKN2 regulates GDF11/8. This observation is 200 supported by in vitro evidence suggesting that WFIKKN2 has high affinity for GDF8 and 201 GDF11 28 . This finding illustrates how delineation of causal genes at trans-associated loci 202 may help identify additional drug targets in pathways known to be relevant to disease. 203 204 Identifying causal pathways underlying disease susceptibility loci 205 GWAS have identified thousands of loci associated with common diseases, but the pathways 206 by which most variants influence disease susceptibility await discovery. To identify 207 intermediate links between genotype and disease, we overlapped pQTLs with disease-208 associated genetic variants identified through GWAS (p<5x10 -8 ). 152 of our pQTLs were 209 strongly correlated (r 2 ≥ 0.8) with variants significantly associated with disease 210 ( Supplementary Table 10 ), including 38 with cis associations, 109 with trans associations 211 and 5 with both. In the examples below, we illustrate how our findings provide novel insights 212 spanning a wide range of disease domains including autoimmunity, cancer and 213 cardiovascular disease. 214
215
Our trans pQTL data implicate previously unsuspected proteins as mediators through which 216 genetic loci exert their influence on disease risk. For example, GWAS have identified a 217 missense allele (rs3197999:A, p.Arg703Cys) in MST1 on chromosome 3 that increases risk 218 of inflammatory bowel disease (IBD) ( Figure 3 ) 29,30 , and decreases plasma MST1 levels 31 . 219
We show that this polymorphism acts in trans to reduce abundance of BLIMP1, encoded by 220 PRDM1 on chromosome 6 (Figure 3, Supplementary Table 1 ). BLIMP1 is a transcriptional 221 master regulator that plays a critical role in the terminal differentiation of immune cells. 222
Intriguingly, there is another IBD association signal in the intergenic region adjacent to 223 PRDM1 on chromosome 6 ( Figure 3 ) 30 . Both PRDM1 and its neighbour ATG5, which 224 encodes a protein involved in autophagy, are plausible candidate genes at this locus. Our data 225 implicate BLIMP1 as a previously unidentified mediator of the IBD association in MST1 on 226 chromosome 3. In addition, our results provide indirect support for the hypothesis that 227 PRDM1 is the causal gene underlying the chromosome 6 association. 228
229
We next show how pQTL data can elucidate pathogenic mechanisms. Anti-neutrophil 230 cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease characterised by 231 autoantibodies to the neutrophil proteases proteinase-3 (PR3) or myeloperoxidase (MPO). 232
Clinico-pathological features mirror antibody specificity, with granulomatous inflammation 233 typically correlating with anti-PR3 antibodies (PR3+ AAV). GWAS have identified signals 234 in PRTN3 (encoding PR3) and SERPINA1 (encoding alpha1-antitrypsin, an inhibitor of PR3) 235 specific to PR3+ AAV 32 . We identified a cis pQTL immediately upstream of PRTN3 236 ( Supplementary Table 1 ). By linking the risk allele at PRTN3 to higher plasma levels of the 237 autoantigen PR3, our data strongly suggest a pathogenic role of anti-PR3 antibodies in this 238 disease. 239
240
The vasculitis risk allele at the SERPINA1 locus (rs28929474:T, also known as the 'Z' allele) 241 is a missense variant (p.Glu366Lys) which results in defective secretion of alpha1-242 antitrypsin. We found that the Z allele was not only associated with lower plasma alpha1-243 antitrypsin, but was also a pQTL "hotspot" associated with 13 proteins using our 244 conservative significance threshold (p<1.5x10 -11 ) ( Figure 4 ) and 19 at p<5x10 -8 . This finding 245
illustrates how a single mutation can lead to widespread perturbation of downstream proteins. 246
One of these proteins was NCF2 (neutrophil cytosolic factor 2), which plays a key role in the 247 neutrophil oxidative burst. Mutations in NCF2 can result in a rare condition known as chronic 248 granulomatous disease, which like PR3+ AAV exhibits granulomatous inflammation. Our 249 results suggest NCF2 may mediate this characteristic feature of PR3+ AAV. 250 251
Causal evaluation of candidate proteins in disease 252
Association of plasma protein levels with disease does not necessarily imply causation. To 253 help establish causality, we employed the principle of Mendelian randomization (MR) 33 . In 254 contrast with observational studies, which are liable to confounding and/or reverse causation, 255 MR analysis is akin to a "natural" randomised controlled trial, exploiting the random 256 allocation of alleles at conception (Extended Data Figure 6 ). Consequently, if a genetic 257 variant that specifically influences levels of a protein is also associated with disease risk, then 258 it provides strong evidence of the protein's causal role. For example, serum levels of PSP-94 259 (MSMB), a hormone synthesized by the prostate gland and secreted into seminal fluid, are 260 lower in patients with prostate cancer; PSP-94 is therefore a candidate biomarker for prostate 261 cancer 34 . However, it is debated whether PSP-94 plays a causal role in tumorigenesis. We 262 identified a cis pQTL for PSP-94 at a prostate cancer susceptibility locus 35 and showed that 263 the risk allele is associated with lower PSP-94 plasma levels, supporting a protective role for 264 the protein. 265
266
In an approach that extends classic MR analysis, we leveraged multi-variant MR analysis 267 methods to distinguish causal genes among multiple plausible candidates at disease loci 268 (Methods), exemplified by the IL1RL1-IL18R1 locus. We identify four proteins that each had 269 cis pQTLs at this locus ( Supplementary Table 1 ), which has been associated with a range of 270 immune-mediated diseases including atopic dermatitis 36 . We created a genetic score for each 271 protein using multiple protein-increasing alleles. Initial "one-protein-at-a-time" analysis 272 identified associations of the scores for IL18R1 (p=9.3x10 -72 ) and IL1RL1 (p=5.7x10 -27 ) 273 with atopic dermatitis risk ( Figure 5a ). In addition, we found a weak association for IL1RL2 274 (p=0.013). We then mutually adjusted these associations for one another to account for the 275 effects of the variants on multiple proteins. While the association of IL18R1 remained 276 significant (p=1.5x10 -28 ), the association of IL1RL1 (p=0.01) was attenuated. In contrast, the 277 association of IL1RL2 (p=1.1x10 -69 ) became much stronger, suggesting that IL1RL2 and 278 IL18R1 are the causal proteins influencing risk of atopic dermatitis at this locus. 279
280
We also used multiple cis-associated variants to evaluate whether macrophage 281 metalloelastase (MMP-12) plays a causal role in coronary disease. Since MMP-12 is known 282 to play a role in lung damage, MMP-12 inhibitors are being tested in chronic obstructive 283 pulmonary disease (COPD). Observational studies report associations of higher levels of 284 plasma MMP-12 with recurrent cardiovascular events 37,38 . In contrast, our multi-allelic 285 genetic score, which explains 14% of the variation in plasma MMP-12 levels (Methods), 286 indicates that genetic predisposition to higher MMP-12 levels is associated with decreased 287 coronary disease risk (p=2.8x10 -13 ) ( Figure 5b ) and decreased large artery atherosclerotic 288 stroke risk 39 . As MMP-12 is released from macrophages in response to cardiovascular 289 injury 40 , it is possible that higher MMP-12 levels are cardioprotective. Hence, our results 290 identify a potential cardiovascular safety concern for MMP-12 inhibitors, particularly as 291 patients with COPD are at high baseline cardiovascular risk due to smoking history. 292 293 Drug target prioritisation 294 Because therapeutic targets implicated by human genetic data are likely to play causal roles 295 in disease, drugs directed at such targets have greater likelihood of success 41 . According to 296 the Informa Pharmaprojects database (Citeline), 244 of the proteins linked to a disease-297 associated variant by our pQTL data are drug targets ( Supplementary Table 11 ). Of the 298 proteins we identified as associated with disease susceptibility loci, 49 are targets of already 299 approved drugs such as tocilizumab and ustekinumab ( Supplementary Table 12 ). 300
301
To identify additional indications for existing drugs, we investigated disease associations of 302 pQTLs for proteins already targeted by licensed drugs. Our results suggest potential drug "re-303 purposing" opportunities ( Supplementary Table 12 ). For example, we identified a cis pQTL 304 for RANK (encoded by TNFRSF11A) at a locus associated with Paget's disease 42 , a condition 305 characterised by excessive bone turnover leading to deformity and fracture. Standard 306 treatment consists of osteoclast inhibition with bisphosphonates, originally developed as anti-307 osteoporotic drugs. Denosumab, another anti-osteoporosis drug, is a monoclonal antibody 308 targeting RANKL, the ligand for RANK. Our data suggest denosumab may be a useful 309 alternative for patients with Paget's disease in whom bisphosphonates are contra-indicated, a 310 hypothesis supported by clinical case reports 43, 44 . 311
312
To evaluate targets for drugs currently under development, we considered the example of 313 glycoprotein Ib platelet alpha subunit (GP1BA), the receptor for von Willebrand factor. 314
Drugs directed at GP1BA are in pre-clinical development as anti-thrombotic agents and in 315 phase 2 trials to treat thrombotic thrombocytopenic purpura, a life-threatening disorder. We 316 identify a trans pQTL for GP1BA at the pleiotropic SH2B3/BRAP locus, which is associated 317 with platelet count 45 , myocardial infarction and stroke. The risk allele for cardiovascular 318 disease increases both plasma GP1BA and platelet count, suggesting a mechanism by which 319 this locus affects disease susceptibility. As a confirmation of the link between GP1BA and 320 the platelet count, we found a directionally concordant cis pQTL for GP1BA at a platelet 321 count-associated variant ( Supplementary Table 12 ). Collectively, these results suggest that 322 targeting GP1BA may be efficacious in conditions characterised by platelet aggregation such 323 as arterial thrombosis. More generally, our data provide a foundation for generating 324 hypotheses about targets for new drug development through the approach of linking genetic 325 factors to disease via specific proteins ( Supplementary Table 12 ). 326 327
Discussion

328
We conducted protein measurements of unprecedented scope and scale to reveal genetic 329 control of the human plasma proteome. Our discoveries enabled identification of important 330 consequences of natural perturbations in the plasma proteome. First, we identified the 331 downstream effects of alterations in specific protein levels, revealing novel regulators of 332 protein pathways. Second, we used plasma proteins to uncover intermediate molecular 333
pathways that connect the genome to disease endpoints. Previous investigation has focused 334 on genes in the vicinity of disease susceptibility loci. By contrast, we made key advances 335 through use of trans pQTLs to implicate previously unsuspected proteins encoded by distant 336 genes. Third, we established causal roles for protein biomarkers in vascular, neoplastic, and 337 autoimmune diseases using the principle of Mendelian randomization (MR). Proteins provide 338 an ideal paradigm for MR analysis because they are under proximal genetic control. Whereas 339 MR studies of plasma proteins have been constrained by availability of few suitable genetic 340 instruments, our data remedy this bottleneck by furnishing an extensive toolkit. Fourth, we 341 introduced an approach that should help reduce the unsustainably high attrition rates of drugs 342 in pharmaceutical pipelines. Overall, our study foreshadows major advances in post-genomic 343 science through increasing application of novel bioassay technologies to major population 344 blood samples for research purposes were collected in 6ml EDTA tubes using standard 363 venepuncture protocols. The tubes were inverted three times and transferred at room 364 temperature to UK Biocentre (Stockport, UK) for processing. Plasma was extracted into two 365 0.8ml plasma aliquots by centrifugation and subsequently stored at -80°C prior to use. 366 367 Protein measurements 368 We used a multiplexed, aptamer-based approach (SOMAscan assay) to measure the relative 369 concentrations of 3,620 plasma proteins/protein complexes assayed using 4,034 aptamers 370 ("SOMAmer reagents", hereafter referred to as "SOMAmers"). The assay extends the lower 371 limit of detectable protein abundance afforded by conventional approaches (e.g., 372 immunoassays), measuring both extracellular and intracellular proteins (including soluble 373 domains of membrane-associated proteins), with a bias towards proteins likely to be found in 374 the human secretome (Extended Data Figure 7a criteria for these values are between 0.4 and 2.5 based on historical runs. SOMAmer-level 394 QC made use of replicate calibrator samples using the same study matrix (plasma) to correct 395 for between-run variability. The acceptance criteria for each SOMAmer is that the calibration 396 scale factor be less than 0.4 from the median for each of the plates run. In addition, at the 397 plate level, the acceptance criteria are that the median of the calibration scale factors is 398 between 0.8 and 1.2, while 95% of individual SOMAmers must be less than 0.4 from the 399 median within the plate. 400
401
In addition to QC processes routinely conducted by SomaLogic, we measured protein levels 402 of 30 and 10 pooled plasma samples randomly distributed across plates for subcohort 1 and 403 subcohort 2, respectively. This approach, which involved masking laboratory technicians to 404 the presence of pooled samples, enabled estimation of the reproducibility of the protein 405 assays in directly relevant samples. We calculated coefficients of variation (CVs) for each 406 SOMAmer within each subcohort by dividing the standard deviation by the mean of the 407 pooled plasma sample protein readouts. In addition to passing SomaLogic QC processes, we 408 required SOMAmers to have a CV≤20% in both subcohorts. Eight non-human protein 409 targets were also excluded, leaving 3,283 SOMAmers (mapping to 2,994 unique 410 proteins/protein complexes) for inclusion in the GWAS. transformed protein levels were then adjusted in a linear regression for age, sex, duration 464 between blood draw and processing (binary, £1 day/>1day) and the first three principal 465 components of ancestry from multi-dimensional scaling. The protein residuals from this 466 linear regression were then rank-inverse normalized and used as phenotypes for association 467 testing. Univariate linear regression using an additive genetic model was used to test genetic 468 associations. Association tests were carried out on allelic dosages to account for imputation 469 uncertainty ("-method expected" option) using SNPTEST v2.5.2 55 . 470 471 Meta-analysis and statistical significance 472 Association results from the two subcohorts were combined via fixed-effects inverse-473 variance meta-analysis combining the betas and standard errors using METAL 56 . Genetic 474 associations were considered to be genome-wide significant based on a conservative strategy 475 requiring associations to have (i) a meta-analysis p-value<1.5x10 -11 (genome-wide threshold 476 of p=5x10 -8 Bonferroni corrected for 3,283 aptamers tested), (ii) at least nominal significance 477 (p<0.05) in both subcohorts, and also (iii) consistent direction of effect across subcohorts. 478
We did not observe significant genomic inflation (mean inflation factor was 1.0, standard 479 deviation=0.01) (Extended Data Figure 8 ). 480 481
Refinement of significant regions 482
To identify distinct non-overlapping regions associated with a given SOMAmer, we first 483 defined a 1Mb region around each significant variant for that SOMAmer. Starting with the 484 region containing the variant with the smallest p-value, any overlapping regions were then 485 merged and this process was repeated until no more overlapping 1Mb regions remained. The 486 variant with the lowest p-value for each region was assigned as the "regional sentinel 487 variant". Due to the complexity of the Major Histocompatibility Region (MHC) region, we 488 treated the extended MHC region (chr6:25.5-34.0Mb) as one region. To identify whether a 489 region was associated with multiple SOMAmers, we used an LD-based clumping approach. 490
Regional sentinel variants in high LD (r 2 ³0.8) with each other were combined together into a 491 single region. 492 493 Conditional analyses 494 To identify conditionally significant signals, we performed approximate genome-wide step-495 wise conditional analysis using GCTA v1.25.2 57 using the "cojo-slct" option. We used the 496 same conservative significance threshold of p=1.5x10 -11 as for the univariate analysis. As 497 inputs for GCTA, we used the summary statistics (i.e. betas and standard errors) from the 498 meta-analysis. Correlation between variants was estimated using the hard-called genotypes 499 (where a genotype was called if it had a posterior probability of >0.9 following imputation or 500 set to missing otherwise) in the merged genetic dataset, and only variants also passing the 501 univariate genome-wide threshold (p<1.5x10 -11 ) were considered for step-wise selection. As 502 the conditional analyses use different data inputs (summarised rather than individual-level 503 data), there were some cases where the conditional analysis failed to include sentinel variants 504 that had borderline significant univariate associations in the step-wise selection. In these 505 instances (n=28), we re-conducted the joint model estimation without step-wise selection in 506 GCTA with variants identified by the conditional analysis in addition to the regional sentinel 507 variant. We report and highlight these cases in Supplementary Table 2 . 508 509 Replication of previous pQTLs 510 We attempted to identify all previously reported pQTLs from GWAS and to assess whether 511 they replicated in our study. We used the NCBI Entrez programming utility in R (rentrez) to 512 perform a literature search for pQTL studies published from 2008 onwards. We searched for 513 the following terms: "pQTL", "pQTLs", and "protein quantitative trait locus". We 514 supplemented this search by filtering out GWAS associations from the NHGRI-EBI GWAS 515
Catalog v.1.0.1 58 (https://www.ebi.ac.uk/gwas/, downloaded April 2016), which has all 516 phenotypes mapped to the Experimental Factor Ontology (EFO) 59 , by restricting to those 517 with EFO annotations relevant to protein biomarkers (e.g. "protein measurement", 518 EFO_0004747). Studies identified through both approaches were manually filtered to include 519 only studies that profiled plasma or serum samples and to exclude studies not assessing 520 proteins. We recorded basic summary information for each study including the assay used, 521 sample size and number of proteins with pQTLs ( Supplementary Table 14 ). To reduce the 522 impact of ethnic differences in allele frequencies on replication rate estimates, we filtered 523 studies to include only associations reported in European-ancestry populations. We then 524 manually extracted summary data on all reported associations from the manuscript or the 525 supplementary material. This included rsID, protein UniProt ID, p-values, and whether the 526 association is cis/trans ( Supplementary Table 15 ). 527
528
To assess replication we first identified the set of unique UniProt IDs that were also assayed 529 on the SOMAscan panel. For previous studies that used SomaLogic technology, we refined 530 this match to the specific aptamer used. We then clumped associations into distinct loci using 531 the same method applied to our pQTL (see Refinement of significant regions). For each 532 locus, we asked if the sentinel SNP or a proxy (r 2 >0.6) was associated with the same 533 protein/aptamer in our study at a defined significance threshold. For our primary assessment, 534
we used a p-value threshold of 10 -4 . We also performed sensitivity analyses to explore factors 535 that influence replication rate (Supplementary Note). 536 537 Candidate gene annotation 538 We defined a pQTL as cis when the most significantly associated variant in the region was 539 (http://www.gtexportal.org/home/datasets). Third, we also queried promoter capture Hi-C 556 data in 17 human primary hematopoietic cell types 61 to identify contacts (with a CHICAGO 557 score >5 in at least one cell type) involving chromosomal regions containing a sentinel 558 variant. We considered gene promoters annotated on either fragment (i.e., the fragment 559 containing the sentinel variant or the other corresponding fragment) as potential candidate 560 genes. Using these three sources of information, we generated a list of candidate genes for the 561 trans pQTLs. A gene was considered a candidate if it fulfilled at least one of the following 562 criteria: (1) it was proximal (intragenic or ±5Kb from the gene) or nearest to the sentinel 563 variant; (2) it contained a sentinel or proxy variant (r 2 >0.8) that was protein-altering; (3) it 564 had a significant cis eQTL in at least one GTEx tissue overlapping with a sentinel pQTL 565 variant (or proxy); or (4) it was regulated by a promoter annotated on either fragment of a 566 chromosomal contact 61 involving a sentinel variant. 567 568 For the "top down" approach, we first identified all genes with a TSS located within the 569 corresponding pQTL region using the GenomicRanges Bioconductor package 62 with  570   annotation  from  a  GRCh37  GTF  file  from  Ensembl where a trans-associated protein shared either an OMIM ID or a KEGG pathway ID with a 583 gene local to the corresponding trans-acting variant, we took this as evidence of a potential 584 functional involvement of that gene. We interrogated protein-protein interaction data by 585 accessing STRINGdb data using the STRINGdb Bioconductor package 68 , whereby we 586 extracted all pairwise interaction scores for each trans-affected protein and all proteins with 587 genes local to the corresponding trans-acting variants. We took the default interaction score 588 of 400 as evidence of an interaction between the proteins, therefore indicating a possible 589 functional involvement for the local gene. In addition to using data from open source 590 databases in our top-down approach we also adopted a "guilt-by-association" (GbA) 591 approach utilising the same plasma proteomic data used to identify our pQTLs. We first 592 generated a matrix containing all possible pairwise Pearson's correlation coefficients between 593 our 3,283 SOMAmers. We then extracted the coefficients relating to our trans-associated 594 proteins and any proteins encoded by genes local to their corresponding trans-acting variants 595 (where available). Where the correlation coefficient was ≥0.5 we prioritised the relevant 596 local genes as being potential mediators of the trans-signal(s) at that locus. 597 598 We report the potential candidate genes for our trans pQTLs from both the "bottom up" and 599 "top down" approaches, highlighting cases where the same gene was highlighted by both 600 approaches. 601 602 Functional annotation of pQTLs 603 Functional annotation of variants was performed using Ensembl VEP v83 using the "pick" 604 option. We tested the enrichment of significant pQTL variants for certain functional classes 605 by comparing to permuted sets of variants showing no significant association with any 606 protein (p>0.0001 for all proteins tested). First the regional sentinel variants were LD-pruned 607 at r 2 of 0.1. Each time the sentinel variants were LD-pruned, one of the pair of correlated 608 variants was removed at random and for each set of LD-pruned sentinel variants and 100 sets 609 of equally sized null permuted variants were sampled matching for MAF (bins of 5%), 610 distance to TSS (bins of 0-0.5Kb, 0.5Kb-2Kb, 2Kb-5Kb, 10Kb-20Kb, 20Kb-100Kb and 611 >100Kb in each direction) and LD (± half the number of variants in LD with the sentinel 612 variant at r 2 of 0.8). This procedure was repeated 100 times resulting in 10,000 permuted sets 613 of variants. An empirical p-value was calculated as the proportion of permuted variant sets 614
where the proportion that are classified as a particular functional group exceeded that of the 615 test set of sentinel pQTL variants, and we used a significance threshold of p=0.005 (0.05/10 616 functional classes tested). 617 618 Evidence against aptamer-binding effects at cis pQTLs 619 All protein assays that rely on binding (e.g. of antibodies or SOMAmers) are susceptible to 620 the possibility of binding-affinity effects, where protein-altering variants (PAVs) (or their 621 proxies in LD) are associated with protein measurements due to differential binding rather 622 than differences in protein abundance. To account for this potential effect, we performed 623 conditional analysis at all cis pQTLs where the sentinel variant was in LD (0.1£r 2 ≤0.9) with 624 a PAV in the gene(s) encoding the associated protein. Testing for regulatory and functional enrichment 637 We tested whether our pQTLs were enriched for functional and regulatory characteristics 638 using GARFIELD v1.2.0 18 . GARFIELD is a non-parametric permutation-based enrichment 639 method that compares input variants to permuted sets matched for number of proxies (r 2 ≥ 640 0.8), MAF and distance to the closest TSS. It first applies "greedy pruning" (r 2 <0.1) within a 641 1Mb region of the most significant variant. GARFIELD annotates variants with more than a 642 thousand features, drawn predominantly from the GENCODE, ENCODE and ROADMAP 643 projects, which includes genic annotations, histone modifications, chromatin states and other 644 regulatory features across a wide range of tissues and cell types. 645
646
The enrichment analysis was run using all variants that passed our Bonferroni-adjusted 647 significance threshold (p<1.5x10 -11 ) for association with any protein. For each of the 648 matching criteria (MAF, distance to TSS, number of LD proxies), we used five bins. In total 649 we tested 25 combinations of features (classified as transcription factor binding sites, FAIRE-650 seq, chromatin states, histone modifications, footprints, hotspots, or peaks) with up to 190 651 cell types from 57 tissues, leading to 998 tests. Hence, we considered enrichment with a p<5 652 x10 -5 (0.05/998) to be statistically significant. 653 654 Disease annotation 655 To identify diseases that our pQTLs have been associated with, we queried our sentinel 656 variants and their strong proxies (r 2 ³0.8) against publicly available disease GWAS data using 657 Cis eQTL overlap and enrichment of cis pQTLs for cis eQTLs 664 Each regional sentinel cis variant its strong proxies (r 2 ³0.8) were queried against publicly 665 available eQTL association data using PhenoScanner. Cis eQTL results were filtered to retain 666 only variants with p<1.5x10 -11 . Only cis eQTLs for the same gene as the cis pQTL protein 667 were retained. To assess whether our cis pQTLs were more likely to also be cis eQTLs than 668 non-pQTL variants, we used data from the GTEx project v6, due to the availability of 669 genome-wide association results across a wide range of tissues and cell-types. GTEx results 670 were filtered to contain only variants lying in cis (i.e., within 1Mb) of genes that encode 671 proteins analysed in our study and only variants in both datasets were utilised. 672
673
For the enrichment analysis, the cis pQTL sentinel variants were first LD-pruned (r 2 <0.1) 674 and the proportion of sentinel cis pQTL variants that are also eQTLs (at p<1.5x10 -11 ) for the 675 same protein/gene was compared to a permuted set of variants that were not pQTLs 676 (p>0.0001 for all proteins). We generated 10,000 permuted sets of null variants matched for 677 MAF, distance to TSS and LD (as described for functional annotation enrichment in 678
Functional annotation of pQTLs). An empirical p-value was calculated as the proportion of 679 permuted variant sets where the proportion that are also cis eQTLs exceeded that of the test 680 set of sentinel cis pQTL variants. Results were similar in sensitivity analyses using the 681 standard genome-wide significance threshold of p<5x10 -8 for the eQTLs (13.0% for whole 682 blood, 18.7% for LCLs, 17.1% for liver and 13.4% for monocytes) as well as also using only 683 the sentinel variants at cis pQTLs that were robust to adjusting for PAVs, suggesting our 684 results are robust to choice of threshold and potential differential binding effects. 685 686
Mediation of the GDF11/8 trans pQTL by WFIKKN2 levels 687
To assess whether the trans pQTL for GDF11/8 in the WFIKKN2 gene region was mediated 688 by WFIKKN2 levels, we first regressed the rank inverse transformed residuals for GDF11/8 689 used for the GWAS against the WFIKKN2 residuals, adjusting for subcohort. The residuals 690 from this regression were subsequently regressed against allelic dosages for each variant in 691 the WFIKKN2 region. As there were two SOMAmers targeting WFIKKN2, we tested both to 692 see if similar results were obtained. Regional association plots were made using Gviz 70 . 693 695 In Mendelian randomization (MR), genetic variants are used as "instrumental variables" (IV) 696 for assessing the causal effect of the exposure (here a plasma protein) on the outcome (here 697 disease). 698 699
Selection of genetic instruments for Mendelian randomization
Proteins in the IL1RL1-IL18R1 locus and atopic dermatitis 700
To identify the likely causal proteins that underpin the previous genetic association of the 701 IL1RL1-IL18R1 locus (chr11:102.5-103.5Mb) with atopic dermatitis (AD) 36 , we used a 702 multivariable MR approach. For each protein encoded by a gene in the IL1RL1-IL18R1 locus, 703
we took genetic variants that had a cis association at p<1x10 -4 and 'LD-pruned' them at 704 r 2 <0.1. We then used these variants as instrumental variables for their respective proteins in 705 univariate MR. For multivariable MR, association estimates for all proteins in the locus were 706 extracted for all instruments. We used PhenoScanner to obtain association statistics for the 707 selected variants in the European-ancestry population of a recent large-scale GWAS meta-708 analysis 36 . Where the relevant variant was not available, the strongest proxy with r 2 ≥0.8 was 709 used. 710
711
MMP-12 and coronary heart disease (CHD) 712
To test whether plasma MMP-12 levels have a causal effect on risk of CHD, we selected 713 genetic variants in the MMP12 gene region to use as instrumental variables. We constructed a 714 genetic score comprising 17 variants that had a cis association with MMP-12 levels at 715 p<5x10 -8 and that were not highly correlated with one another (r 2 <0.2). To perform 716 multivariable MR, we used association estimates for these variants with other MMP proteins weighting matrix Ω has terms Ω * 6 * 7 = ,* 6 ,* 7 ρ * 6 * 7 , and ρ * 6 * 7 is the correlation between 737 the 9 th and : th variants. where T is a matrix transpose. This is the estimate and standard error from the regression 748 model fixing the residual standard error to 1 (equivalent to a fixed-effects model in a meta-749 analysis). 750 751 Genetic variants in univariate MR need to satisfy three key assumptions to be valid 752 instruments: 753
(1) the variant is associated with the risk factor of interest (i.e., the protein level), 754
(2) the variant is not associated with any confounder of the risk factor-outcome 755 association, 756
(3) the variant is conditionally independent of the outcome given the risk factor and 757 confounders. 758
759
To account for potential effects of functional pleiotropy 74 , we performed multivariable MR 760 using the weighted regression-based method proposed by Burgess et al 75 We performed two sensitivity analyses to determine the robustness of the Mendelian 781 randomization findings. First, we measured plasma MMP-12 levels using a different method 782 (proximity extension assay; Olink Bioscience, Uppsala, Sweden 76,77 ) in a sub-sample of 141 783 individuals, and used this to derive genotype-MMP12 effect estimates for the 17 variants in 784 our genetic score. Second, we obtained effect estimates from a pQTL study based on 785 SOMAscan assay measurements in an independent sample of ~1,000 individuals 7 . In both 786 cases the genetic score reflecting higher plasma MMP-12 was associated with lower risk of 787
CHD. 788 789
Overlap of pQTLs with drug targets 790 We used the Informa Pharmaprojects database from Citeline to obtain information on drugs 791 that target proteins assayed on the SOMAscan platform. This is a manually curated database 792 that maintains profiles for >60,000 drugs. For our analysis, we focused on the following 793 information for each drug: protein target, indications, and development status. We included 794 drugs across the development pipeline, including those in pre-clinical studies or with no 795 development reported, drugs in clinical trials (all phases), and launched/registered drugs. For 796 each protein assayed, we identified all drugs in the Informa Pharmaprojects with a matching 797 protein target based on UniProt ID. When multiple drugs targeted the same protein, we 798 selected the drug with the latest stage of development. 799 800 For drug targets with significant pQTLs, we identified the subset where the sentinel variant or 801 proxy variants in LD (r 2 >0.6) are also associated with disease risk through PhenoScanner. 802
We used an internal Merck auto-encoding method to map GWAS traits and drug indications 803 to a common set of terms from the Medical Dictionary for Regulatory Activities (MedDRA). 804
MedDRA terms are organized into a hierarchy with five levels. We mapped each GWAS trait 805 and indication onto the 'Lowest Level Terms' (i.e. the most specific terms available). All 806 matching terms were recorded for each trait or indication. We matched GWAS traits to drug 807 indications based on the highest level of the hierarchy, called 'System Organ Class' (SOC). 808
We designated a protein as 'matching' if at least one GWAS trait term matched with at least 809 one indication term for at least one drug. 
